Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

LEO Pharma Announces New Long-Term Data for SPEVIGO® (spesolimab-sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026

Nearly 75% of patients treated with SPEVIGO experienced no generalized pustular psoriasis flares over three years, supporting its role in long-term disease management.

Summary by Enid News & Eagle
MADISON, N.J.--(BUSINESS WIRE)--Mar 27, 2026-

3 Articles

Hastings TribuneHastings Tribune
+2 Reposted by 2 other sources
Center

LEO Pharma Announces New Long-Term Data for SPEVIGO® (spesolimab-sbzo) Injection in Adults with Generalized Pustular Psoriasis at AAD 2026

MADISON, N.J.--(BUSINESS WIRE)--Mar 27, 2026-

·Nebraska, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources are Center
50% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news in on Friday, March 27, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Madison, New Jersey icon

Madison, New Jersey

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal